CORAL GABLES, Fla. – Relmada Therapeutics , Inc. (NASDAQ:), a biotech company focusing on central nervous system (CNS) diseases, reported today that its Phase 3 study of REL-1017 for major depressive disorder (MDD), known as Reliance II, is unlikely to meet its primary efficacy endpoint. The news impacts the company’s $83.6 million market capitalization, though InvestingPro analysis suggests the stock is currently trading below its Fair Value. The Independent (LON:) Data Monitoring Committee (DMC) conducted a pre-planned interim analysis and found the study to be futile, although no new safety concerns were identified.
REL-1017, an adjunctive treatment for MDD to be used alongside other approved antidepressants, had shown promise as a novel NMDA receptor channel blocker. Despite the setback, Relmada CEO Sergio Traversa expressed gratitude to the patients and investigative sites involved in the program and stated that the company would review the full dataset to determine the future of REL-1017.
In addition to this development, Relmada will proceed with its Phase 1 study of REL-P11, an investigational agent targeting metabolic disease. This decision is backed by the company’s strong financial position, with approximately $54.1 million in cash and cash equivalents as of September 30, 2024. InvestingPro data confirms the company’s solid liquidity, with a current ratio of 6.89 and cash holdings exceeding debt obligations. Subscribers can access 5 additional key ProTips about RLMD’s financial health.
REL-P11 is part of a novel psilocybin and derivatives program acquired by Relmada in July 2021, with potential applications in treating metabolic diseases supported by data presented at the American Society for the Study of Liver Disease (AASLD 2023).
The information in this article is based on a press release statement from Relmada Therapeutics. The company’s forward-looking statements, as per the Private Securities Litigation Reform Act of 1995, indicate management’s expectations and projections, which are subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated. For a comprehensive analysis of RLMD’s financial health, valuation metrics, and future prospects, investors can access the detailed Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert insights and actionable intelligence.
In other recent news, Relmada Therapeutics has released its Q3 financials, reporting a decrease in cash and investments to $54.1 million and a net loss of $21.7 million. The company’s focus remains on the development of REL-1017 for the treatment of major depressive disorder (MDD), with an interim analysis for the Reliance 2 Phase 3 study expected by the end of 2024. Research and development expenses have risen to $11.1 million, funding ongoing studies including a Phase 1 safety study for a psilocybin-based candidate and plans for a Phase 2a study in the upcoming year. In addition, the company plans to enroll between 300 and 340 patients for the Reliance 2 Phase 3 study. Despite financial losses, Relmada Therapeutics continues its research and development efforts, particularly with REL-1017, which has potential as a significant adjunct treatment for MDD. These are among the recent developments concerning the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
